Overview


According to FutureWise analysis the market for Plasmid DNA Manufacturing in 2023 is US$ 1.52 billion, and is expected to reach US$ 5.66 billion by 2031 at a CAGR of 17.90%.

Plasmid DNA is critical in today's healthcare industry. It can be used directly for therapeutic purposes, such as gene therapy or vaccine antigen production, or indirectly for a variety of research purposes, such as gene mapping, gene cloning, and so on, to help prevent diseases such as cystic fibrosis or Huntington's disease. These include the use of plasmid DNA as a critical starting material for transient transfection to construct viral-vector structures such as lentivirus or Adeno-associated virus (AAV), as well as transitory proteins in development such as monoclonal antibodies. Gene therapy is a rapidly developing medical field that promises novel therapies for people suffering from a variety of ailments.

Due to its diverse applications in the treatment of diseases, the medical procedures of gene therapy and genetic vaccination have profoundly altered human existence and are gaining popularity. Plasmid DNA is a gene therapy product that inserts therapeutic genes into human cells using circular DNA molecules that have undergone genetic engineering. Moreover, plasmid DNA is an essential building block for cutting-edge treatments like viral vectors and RNA vaccinations. The increasing demand for plasmid DNA in various medical therapies, the increasing clinical success of using plasmid DNA in medical procedures, the rising prevalence of people suffering from multiple diseases, and the quick growth advancements in the biopharmaceutical industry are all contributing to the expected expansion of the global plasmid DNA manufacturing market.

FutureWise Market Research has published a report that provides an insightful analysis of Plasmid DNA Manufacturing Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the Plasmid DNA Manufacturing Market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Cobra Biologics and Pharmaceutical Services
  • VGXI, Inc.
  • Aldevron
  • Kaneka Corporation
  • Nature Technology Corporation
  • PlasmidFactory GmbH & Co. KG.
  • Cell and Gene Therapy Catapult
  • Waisman Biomanufacturing
  • LakePharma, Inc.
  • MeiraGTx Limited
  • Eurofins Genomics
  • Vigene Biosciences
  • Luminous BioSciences (LBS), LLC.
  • Genscript Biotech Corporation
  • GENEWIZ
  • Creative Biogene
  • Akron Biotech
  • Biomay
  • JAFRAL Ltd.
  • Cepham Life Sciences
  • Delphi Genetics
  • Biomiga
  • GeneImmune Biotechnology Corp.
  • Lonza
  • Greenpak Biotech Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

Cobra Biologics, Cognate BioServices' gene therapy subsidiary, announced a multi-phase expansion of its plasmid DNA services in January 2021 as part of the company's Gene Therapy services expansion project for viral vectors and plasmid DNA. This includes a fourfold increase in HQ (High Quality) DNA manufacturing capacity at its European locations, as well as new clinical and commercial GMP DNA facilities.

The market for plasmid DNA production is growing as a result of rising research demand in the areas of gene therapy and genetic immunisation. In the modern healthcare sector, plasmid DNA is crucial. The plasmid DNA can be utilised for research as well as the production of vaccine antigens and gene therapy. The expansion of the market is being driven by the rise in patients seeking gene therapy. Also, the market for plasmid DNA synthesis is being driven by the biopharmaceutical sector's explosive rise. Additionally, the increased use of gene therapy to treat serious illnesses like cancer, autoimmune diseases, and others is anticipated to boost demand for plasmid DNA production in the near future. Furthermore, the desire for innovative manufacturing technologies for the commercial manufacture of plasmid DNA is being driven by the expanding demand for biopharmaceutical industry advancements. The increase in partnerships and cooperation amongst the numerous organisations operating in this field reflects the rising need for plasmid DNA production. However, there are major backlogs and lengthy waiting lists for contract manufacturers who can supply plasmid DNA of GMP standard. The market and patient expectations could be harmed by the industry's inability to deliver high-quality DNA in a timely manner, which could hinder R&D pipeline advancement. These factors are expected to hinder the market of plasmid DNA manufacture.

By Disease

  • Infectious Disease
  • Cancer
  • Genetic Disorder

By Grade

  • GMP Grade
  • R&D Grade

By Application

  •  DNA Vaccines
  • Gene Therapy
  • Immunotherapy
  • Other Applications

By Development Phase

  • Pre-Clinical Therapeutics
  • Clinical Therapeutics
  • Marketed Therapeutics

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. The presence of various biopharmaceutical industry companies in North America significantly boosts the need for plasmid DNA. The region is also noted for its high disposable income, rising consumer knowledge of gene therapies, enhanced healthcare infrastructure, and rising use of gene therapy to treat a range of illnesses. Biopharmaceutical companies in the US have discovered around 362 treatments that are now being tested in clinical settings. The plasmid DNA manufacturing market in North America is expanding thanks to the faster-paced research and development in the sector in the US rapidly.

Moreover, by disease, the infectious disease segment held the top spot in the global plasmid DNA manufacturing market in 2022. For instance, based on disease, infectious disease holds 58.9% share in the global market in 2022, followed by genetic disorders 27% and cancer 14.1% as it offers strong immunity through vaccine antigens and inhibits pathogen infections. Also, this market's growth is greatly accelerated by the expanding usage of vectors in cancer treatment medicines.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Plasmid DNA Manufacturing Market By Disease, By Grade, By Application, By Development Phase and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Plasmid DNA Manufacturing Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Plasmid DNA Manufacturing Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Plasmid DNA Manufacturing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Plasmid DNA Manufacturing Market, By Disease Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Infectious Disease
        2. Cancer
        3. Genetic Disorder

  • 8.   Plasmid DNA Manufacturing Market, By Grade Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. GMP Grade
        2. R D Grade

  • 9.   Plasmid DNA Manufacturing Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. DNA Vaccines
        2. Gene Therapy
        3. Immunotherapy
        4. Other Applications

  • 10.   Plasmid DNA Manufacturing Market, By Development Phase Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pre-Clinical Therapeutics
        2. Clinical Therapeutics
        3. Marketed Therapeutics

  • 11.   North America Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Plasmid DNA Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Cobra Biologics and Pharmaceutical Services
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. VGXI, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Aldevron
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Kaneka Corporation
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Nature Technology Corporation
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. PlasmidFactory GmbHCo. KG.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cell and Gene Therapy Catapult
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Waisman Biomanufacturing
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. LakePharma, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. MeiraGTx Limited
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Eurofins Genomics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Vigene Biosciences
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Luminous BioSciences (LBS), LLC.
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Genscript Biotech Corporation
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. GENEWIZ
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Creative Biogene
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Akron Biotech
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Biomay
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. JAFRAL Ltd.
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Cepham Life Sciences
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Delphi Genetics
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Biomiga
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. GeneImmune Biotechnology Corp.
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. Lonza
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. Greenpak Biotech Ltd
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients